Last edition
News about "HER2-Negative Breast Cancer"
US FDA Approves ETCAMAH Plus CDK4/6 Inhibitor for Advanced HR-Positive Breast Cancer
US approves ETCAMAH (camizestrant) plus a CDK4/6 inhibitor for first-line advanced HR-positive breast cancer, reducing progression or death risk by 56 percent.
HER2-negative Breast Cancer | 05/09/2026 | By News Bureau
Pathos AI, AstraZeneca Partner to Advance AI-Driven Breast Cancer Therapy into Clinical Development
Pathos AI and AstraZeneca have entered a strategic collaboration to advance AZD4241, an investigational therapy for ER+/HER2- breast cancer, using artificial intelligence to enhance clinical development and precision oncology.
HER2-negative Breast Cancer | 05/08/2026 | By News Bureau | 200
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy